PW01-265 - **NATURALISTIC USE OF THE COATED AND ORALLY DISINTEGRATING TABLETS OF OLANZAPINE IN SCHIZOPHRENIC AND BIPOLAR OUTPATIENTS: EUROPEAN BASELINE RESULTS**

F. Rouillon[1], F. Chartier[2], **S. Kraemer**[3], M. Lukasiewicz[4], S. Tcherny-Lessenot[2], C. Beal[5]

[1]Service de Psychiatrie, Hôpital St Anne, Paris, [2]Pharmacoepidemiology Department, Lilly, Suresnes, France, [3]Medical Department, Lilly, Bad Homburg, Germany, [4]Medical Department, Lilly, Suresnes, France, [5]Statistical Department, Lilly, Erl Wood, UK

Objective: To assess in a naturalistic setting the effectiveness of olanzapine within 12-month follow-up, in schizophrenic and bipolar outpatients.In this abstract, baseline patient characteristics are provided and compared between the olanzapine coated (OC) and orally disintegrating (OD) formulations to investigate prescribing patterns.

Method: ZEN is a 1-year prospective, observational study, carried out in France, Germany and Greece from April'07 to May'09. Baseline patient characteristics were compared using Students-t, Chi^2 or Fisher's-exact tests. Patients who started olanzapine prior to 60 days before the study or for whom the olanzapine formulations could not be determined were excluded from the analysis.

Results: 903 of the 927 enrolled patients were analyzed (45.2% paranoid schizophrenia, 32.2% bipolar disorder). 410 patients received the OC form and 493 the OD form. Distribution of gender was comparable across groups (55.1% male).OC patients were older than OD patients (43.1 vs 39.1 years, $p< 0.001$) and had a longer mean duration of illness (14.4 vs 11.2 years; $p< 0.001$). OD patients were more severely ill irrespective of diagnosis ($p< 0.006$, mean CGI schizophrenia=4.2 vs 3.8, CGI bipolar disorder=4.1 vs 3.7). At initiation, daily dose in OD patients was higher (15.0 vs 10.6 mg, $p< 0.0001$). Based on the 6-level SUMD scale, more OC patients were clearly aware of having a mental disorder (44.7% vs 32.9%; $p< 0.001$). OC patients were more compliant at baseline (mean MARS score 6.6 vs 5.5, $p< 0.001$).

Conclusion: Baseline characteristics show that the utilization of each oral form of olanzapine in outpatient setting is associated with different patient profiles.

https://doi.org/10.1016/S0924-9338(10)71578-9 Published online by Cambridge University Press